[go: up one dir, main page]

MX2023006830A - Inmunocitoquina para activar el receptor il-10ra humano y su uso. - Google Patents

Inmunocitoquina para activar el receptor il-10ra humano y su uso.

Info

Publication number
MX2023006830A
MX2023006830A MX2023006830A MX2023006830A MX2023006830A MX 2023006830 A MX2023006830 A MX 2023006830A MX 2023006830 A MX2023006830 A MX 2023006830A MX 2023006830 A MX2023006830 A MX 2023006830A MX 2023006830 A MX2023006830 A MX 2023006830A
Authority
MX
Mexico
Prior art keywords
immunocytokine
receptor
methods
pharmaceutical compositions
aforementioned
Prior art date
Application number
MX2023006830A
Other languages
English (en)
Inventor
Stanislav Rudolfovich Evdokimov
Valery Vladimirovich Solovyev
Dmitry Valentinovich Morozov
Sergei Andreevich Ageev
Pavel Andreevich Iakovlev
Iana Andreevna Smirnova
Vladimir Sergeevich Tsympilov
Aleksey Vladimirovich Kononov
Iuliia Viktorovna Evdokimovskaia
Elena Sergeevna Kolosova
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2020140807A external-priority patent/RU2810750C2/ru
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of MX2023006830A publication Critical patent/MX2023006830A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere al campo de la biotecnología y la medicina, en particular a una inmunocitoquina para activar el receptor IL-10Ra humano. La invención se refiere además a ácidos nucleicos que codifican dicha inmunocitoquina, vectores de expresión, células huésped y métodos para producirlos, métodos para producir la inmunocitoquina, composiciones farmacéuticas que comprenden la inmunocitoquina mencionada, composiciones farmacéuticas que comprenden la inmunocitoquina mencionada y otros compuestos terapéuticamente activos, métodos para tratar una enfermedad oncológica y los usos de la inmunocitoquina o de las composiciones farmacéuticas de la misma para tratar una enfermedad oncológica.
MX2023006830A 2020-12-10 2021-12-10 Inmunocitoquina para activar el receptor il-10ra humano y su uso. MX2023006830A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2020140807A RU2810750C2 (ru) 2020-12-10 Иммуноцитокин для активации IL-10Rα рецептора человека и его применение
PCT/RU2021/050432 WO2022124950A1 (en) 2020-12-10 2021-12-10 Immunocytokine for activating human il-10ra receptor and use thereof

Publications (1)

Publication Number Publication Date
MX2023006830A true MX2023006830A (es) 2023-07-06

Family

ID=81973601

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006830A MX2023006830A (es) 2020-12-10 2021-12-10 Inmunocitoquina para activar el receptor il-10ra humano y su uso.

Country Status (19)

Country Link
US (1) US20240034764A1 (es)
EP (1) EP4259644A4 (es)
JP (1) JP2023553934A (es)
KR (1) KR20230118919A (es)
CN (1) CN117120461A (es)
AR (1) AR124310A1 (es)
AU (1) AU2021398529A1 (es)
CA (1) CA3201656A1 (es)
CL (1) CL2023001677A1 (es)
CO (1) CO2023007563A2 (es)
CR (1) CR20230243A (es)
EC (1) ECSP23043458A (es)
IL (1) IL303501A (es)
MA (1) MA61003B1 (es)
MX (1) MX2023006830A (es)
PE (1) PE20241070A1 (es)
TW (1) TW202237631A (es)
UY (1) UY39562A (es)
WO (1) WO2022124950A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2882774B1 (en) * 2012-08-08 2018-10-03 Roche Glycart AG Interleukin-10 fusion proteins and uses thereof
US9546203B2 (en) * 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
JP2017506075A (ja) * 2014-02-06 2017-03-02 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト インターロイキン−１０イムノコンジュゲート
JP7544598B2 (ja) * 2017-11-10 2024-09-03 アーモ・バイオサイエンシーズ・インコーポレイテッド 免疫チェックポイント経路阻害剤と併用したインターロイキン－１０の組成物および使用方法
CN113811549A (zh) * 2019-02-21 2021-12-17 Xencor股份有限公司 非靶向和靶向性il-10 fc融合蛋白

Also Published As

Publication number Publication date
UY39562A (es) 2022-05-31
CA3201656A1 (en) 2022-06-16
CL2023001677A1 (es) 2024-01-19
AR124310A1 (es) 2023-03-15
TW202237631A (zh) 2022-10-01
CR20230243A (es) 2023-07-13
EP4259644A1 (en) 2023-10-18
IL303501A (en) 2023-08-01
PE20241070A1 (es) 2024-05-13
KR20230118919A (ko) 2023-08-14
US20240034764A1 (en) 2024-02-01
AU2021398529A9 (en) 2024-10-24
CN117120461A (zh) 2023-11-24
JP2023553934A (ja) 2023-12-26
AU2021398529A1 (en) 2023-06-29
MA61003A1 (fr) 2023-10-31
CO2023007563A2 (es) 2023-07-21
MA61003B1 (fr) 2024-12-31
WO2022124950A1 (en) 2022-06-16
EP4259644A4 (en) 2024-10-16
ECSP23043458A (es) 2023-07-31

Similar Documents

Publication Publication Date Title
CL2021000207A1 (es) Nuevas proteínas de fusión específicas para cd137 y pd-l1
CO2018012482A2 (es) Formulaciones de un inhibidor de lsd1
CO2024005925A2 (es) Moléculas pequeñas para el tratamiento del cáncer
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
CO2020015758A2 (es) Compuestos de purinona y su uso en el tratamiento del cáncer
DOP2019000287A (es) Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi)
BR112016015818A2 (pt) Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1
CL2017002767A1 (es) Nuevas proteínas específicas para cd137.
ECSP077235A (es) Benzamidas sustituidas por trifluoro-metilo como inhibidores de quinasa
MX2018009257A (es) Derivados de benzimidazol como moduladores de ror-gamma.
CL2019002671A1 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1.
MX2023007228A (es) Constructo de arn.
MX2021013491A (es) Nuevas endolisinas de gardnerella y usos de las mismas.
CL2023003017A1 (es) Composiciones y métodos para inhibir cetohexoquinasa (khk)
MX2020005235A (es) Celula humana transformada y uso de la misma.
UY29639A1 (es) Amidas sustituidas con heteroarilo que comprenden un grupo enlazador insaturado o cíclico, y su uso como productos farmacéuticos
CY1124505T1 (el) Κρυσταλλικες μορφες βιλαστινης και μεθοδοι παρασκευης αυτων
CO2024007220A2 (es) Compuestos que contienen heteroátomos y usos de estos
MX2023007229A (es) Constructo de arn.
CL2024002653A1 (es) Anticuerpos anti-gd2, inmunoconjugados y usos terapéuticos de los mismos
CL2023001677A1 (es) Inmunocitoquina para activar el receptor il-10ra humano y su uso
CO2025015421A2 (es) Compuestos heterocíclicos y usos de estos
MX2022005388A (es) Compuestos de pirrolidina y piperidina.
CO2020012484A2 (es) Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd")
AR115878A1 (es) Proteínas de fusión específicas para cd137 y pd-l1